Awards & Advancement

Dixie-Lee Esseltine joins HBS Kraft Precision Medicine Accelerator

Friday, September 29, 2017

Dr. Dixie-Lee Esseltine, formerly the Vice President of Global Clinical Development at Takeda Pharmaceuticals, recently joined the Harvard Business School’s (HBS) Kraft Precision Medicine Accelerator. Esseltine will lead the Accelerator’s Clinical Trials work stream, which is comprised of leading nonprofit organizations (NPOs) and clinical leaders focused on precision medicine. The goal of this work stream is to accelerate the advancement of innovative platform trials across cancers by identifying best practices and sharing knowledge, helping NPOs build their understanding of the design and operation of master protocols, and working with the FDA to improve master protocols.

[Read More]

Rubius Therapeutics appoints Chief Medical Officer Chris Carpenter

Wednesday, September 27, 2017

Rubius Therapeutics, a “Fierce 15” company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, announced the appointment of Chris Carpenter, M.D., Ph.D., as chief medical officer. Dr. Carpenter will oversee Rubius’ clinical and regulatory strategy as the company prepares to enter human clinical trials in 2018. In addition, Rubius announced the appointments of Joanne Protano as vice president of finance; Mark Boshar as vice president of legal affairs; and Theo Proukou as vice president of human resources.

[Read More]

ERT named finalist for 2017 Scrip Award

Friday, September 22, 2017

ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, announced that ERT Trial Oversight—its centralized, cloud-based clinical trial management solution—has been named a finalist for the 2017 Scrip Best Sponsor-Focused Technological Development in Clinical Trials Award.

[Read More]

Envigo adds Craig Boyd and Lizanne Muller

Friday, September 22, 2017

Envigo has made two new appointments to its Executive Committee. The appointments of a Chief Commercial Officer and President of EMEA Operations have been made at a time of growth for Envigo during which the organization has been focused on improving the quality of the customer experience for its global customer base across the pharmaceutical, chemicals, and crop protection industries. Both of the positions report directly into Dr. Adrian Hardy, Chief Executive Officer of Envigo.

[Read More]

Cell Medica appoints Luis Borges as CSO to accelerate R&D for CAR and TCR Programs

Monday, September 18, 2017

Cell Medica, a provider of cell-based immunotherapies for the treatment of cancer, announced the appointment of Luis Borges, Ph.D., as Chief Scientific Officer. Luis will spearhead the Company’s global research group, including teams in London, Zurich and Houston. Luis brings extensive knowledge of cancer immunotherapy from twenty years of experience in the field, including senior positions at Five Prime Therapeutics and Amgen, where he played a senior role in the discovery and development of several blockbuster drugs and therapeutic candidate molecules.

[Read More]

Bracket adds Sam Whitaker as chief technology officer

Monday, September 18, 2017

Bracket, a clinical trial technology and specialty services provider, added Sam Whitaker as Chief Technology Officer (CTO) to its growing team. Whitaker joins Bracket’s leadership team bringing ten years of experience in clinical technology and global infrastructure innovation to the company.

[Read More]

Worldwide Clinical Trials receives finalist nomination for 2017 Scrip Awards

Monday, September 18, 2017

Worldwide Clinical Trials has been announced as a finalist for a second year in the 2017 “Best Contract Research Organization—Full Service Providers” category of the Scrip awards. The six shortlisted companies, chosen by a panel of 16 judges, were chosen for the innovation, dedication and hard work they have displayed in the pharmaceutical and biotech industries during the past year.

[Read More]